The rapid genome testing shortened the average precise genetic diagnosis time from nearly ten months to under two weeks. Credit: Mongkolchon Akesin / Shutterstock. · Medical Device Network · ...
GeneDx Holdings offers AI-driven health intelligence solutions, leveraging the Centrellis platform to analyze clinical and genomic data for disease understanding and personalized healthcare. It ...
Hosted on MSN
GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth
GeneDx raised full year 2025 total revenue guidance to $425 million to $428 million. Exome and genome revenue guidance was increased to $358 million to $361 million, reflecting 53% to 55% growth for ...
Hosted on MSN
GeneDx outlines $540M–$555M 2026 revenue target as company accelerates market expansion with new sales force
Katherine Stueland, President and CEO, indicated that "the fourth quarter was a strong finish to a transformative year for GeneDx," reporting quarterly revenues of $121 million and full year revenues ...
Genomic screening identified conditions missed by standard approaches due to atypical presentations or the absence of biochemical biomarkers, including hearing loss in infants who passed their initial ...
GeneDx Holdings Corp. delivers AI-driven health intelligence solutions, leveraging its platform to analyze multidimensional clinical and genomic data for patient care and disease management. The ...
In 2025, the AAP updated its guidance to recommend exome or genome sequencing as a first-tier test for children with global ...
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third ...
GeneDx Holdings Corp. (WGS) specializes in delivering precise medical diagnostic insights through its expertise in genomic sequencing, data science, and a vast rare disease dataset. The company has ...
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on ...
GeneDx (NASDAQ:WSG) announced plans on Wednesday to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation, to create a leading platform for rare disease diagnostics and newborn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results